Brepocitinib in patients with #dermatomyositis was associated with improvements in cutaneous disease activity, #pruritus, and skin-related quality of life through 52 weeks.
@dermatologyadvisor.bsky.socialExplore
@dermatologyadvisor.bsky.social
@dermatologyadvisor.bsky.socialBrepocitinib in patients with #dermatomyositis was associated with improvements in cutaneous disease activity, #pruritus, and skin-related quality of life through 52 weeks.